2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus.
Ontology highlight
ABSTRACT: Current therapies for systemic lupus erythematosus that target a particular factor or cell type exhibit limited effectiveness. To address this limitation, our focus was on CD132, a subunit common to six inflammatory factor receptors implicated in SLE. Our study revealed heightened CD132 expression in SLE patients' lymphocytes, contributing to the production of pro-inflammatory cytokines and immunoglobulins. We developed a novel humanized anti-CD132 monoclonal antibody, named as 2D4. 2D4 efficiently blocked IL-21 and IL-15, with limited effectiveness against IL-2, thereby suppressing T and B cells without disrupting immune tolerance. In the mouse immunization model, 2D4 virtually inhibited T cell-dependent, antigen-specific B-cell response. In lupus murine models, 2D4 mitigated inflammation
SUBMITTER: Yin H
PROVIDER: S-EPMC11570697 | biostudies-literature | 2024 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA